Pay in 4 interest-free payments of $6.42 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
We outline the potential for multitarget therapy incorporating reninangiotensinaldosterone system inhibitors, sodiumglucose co-transporter-2 inhibitors, incretin-based treatments and nsMRAs to improve cardiovascular and kidney outcomes in patients with overweight/obesity and T2DM
Laxity and fat loss can lead to extra tissue in that area, which is definitely bothersome." Some studies also show that rapid weight loss from GLP-1 medications can lead to a decrease in lean muscle mass
Retatrutide at 12 mg produced 24.2% body weight loss in phase 2 trials, the highest of any single-agent compound tested
Your provider should discuss treatment goals, realistic weight loss expectations (15-22% over 12-16 weeks), injection or oral preferences, and ongoing monitoring frequency before initiating therapy
The dosing starts at 5 mg per day and may gradually increase to 15 mg daily
